

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2877)**

### **TURNOVER FOR THE FIRST QUARTER OF 2022**

The board of directors (the “Board”) of China Shineway Pharmaceutical Group Limited (the “Company”) is pleased to announce that, the turnover of the Company and its subsidiaries (together, the “Group”) for the three months ended 31 March 2022 (“the First Quarter of 2022”) based on its management accounts which have not been reviewed by the auditors, reached RMB878,000,000, representing an increase of 18.0% as compared with the same quarter of 2021, and in particular:

- Turnover of injection products increased by 15.0% to RMB352,000,000;
- Turnover of soft capsule products increased by 22.1% to RMB138,000,000;
- Turnover of granule products decreased by 9.0% to RMB121,000,000;
- Turnover of TCM formula granule products increased by 41.9% to RMB220,000,000; and
- Turnover of products in other forms increased by 27.0% to RMB47,000,000.

In terms of product mix, injection products, soft capsule products, granule products and TCM formula granule products accounted for approximately 40.1%, 15.7%, 13.8% and 25.1% of the total turnover respectively for the First Quarter of 2022.

**Shareholders and investors are advised to exercise caution in dealing in the shares of the Company.**

By order of the Board  
**China Shineway Pharmaceutical Group Limited**  
**Li Zhenjiang**  
*Chairman*

Hong Kong, 11 May 2022

*As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin and Mr. Chen Zhong; the non-executive Director is Mr. Zhou Wencheng and the independent non-executive Directors are Ms. Cheng Li, Prof. Luo Guoan and Mr. Liu Shun Fai.*